XML 15 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities:    
Net earnings (loss) $ 33,873 $ (2,329)
Adjustments to reconcile net earnings (loss) to net cash provided by (used in) operating activities:    
Depreciation and amortization 17,206 16,731
Changes in fair value of interest rate swaps (1,578) 4,233
Changes in fair value of contingent earn-out liability (15,689) (646)
Non-cash lease expense 894 862
Tax receivable agreement liability remeasurement expense 230  
Deferred income tax 164 (2,721)
Stock-based compensation expense 26 28,584
Net foreign exchange difference 145 (1,990)
Other, net (3,237) 11,855
Changes in assets and liabilities:    
Accounts receivable 3,566 (26,034)
Other current assets (4,267) (7,060)
Accounts payable 3,386 6,037
Deferred revenue (1,973) 1,021
Legal liabilities (17,315) 0
Lease liabilities (386) (959)
Accrued expenses and other current liabilities (12,880) (14,164)
Other, net 255 (31)
Net cash provided by (used in) operating activities 2,420 13,389
Cash flows from investing activities:    
Capital expenditures (2,801) (6,811)
Net cash provided by (used in) investing activities (2,801) (6,811)
Cash flows from financing activities:    
Repayment of term loan (1,438) (1,438)
Distributions paid to noncontrolling interest holders (2,721) (5,409)
Share repurchases (62,108) 0
Purchase of Common Units (22,155) 0
Withholding tax paid on behalf of employees on stock-based awards (5,944) (9,321)
Net cash provided by (used in) financing activities (94,366) (16,168)
Effects of exchange rate changes on cash and cash equivalents 1,598 (4,261)
Net increase (decrease) in cash and cash equivalents and restricted cash (93,149) (13,851)
Cash and cash equivalents and restricted cash, beginning of the period 359,202 407,042
Cash and cash equivalents and restricted cash, end of the period 266,053 393,191
Less restricted cash (3,354) (4,236)
Cash and cash equivalents, end of the period $ 262,699 $ 388,955